MA-EXAGRID
22.12.2020 14:02:15 CET | Business Wire | Press release
ExaGrid ® , the industry’s only Tiered Backup Storage solution, today announced that the company had a successful year despite the worldwide struggles associated with the COVID-19 pandemic.
“We are grateful to our customers, reseller partners, and alliance partners who have worked with us to make 2020 such a successful year, in spite of the adversity that we have all faced during the pandemic. We are hopeful that in 2021 that there will be some return to normalcy and look forward to more in-person meetings and events,” said Bill Andrews, President and CEO of ExaGrid. “In the meantime, we have been fortunate that ExaGrid’s industry-leading customer support model already featured remote installation and support, so we have been able to continue our no-contact installation for the safety of our staff and customers without interruption.”
Some of ExaGrid’s major highlights in 2020 include:
- Strong growth in Q1 to Q3, especially in the Americas and EMEA, which included a record number of six and seven-figure purchases for both new and existing customers, with another impressive quarter expected for Q4.
- Continued expansion into the Middle East region, adding new territory managers in Israel, Saudi Arabia and the United Arab Emirates, growing the global sales team, which now covers of 30 countries, with planned expansion to grow to 50 countries over the next two years.
- The release of Software Version 6.0, which included a streamlined navigation experience, user interface improvements, security enhancements, and most notably, the Retention Time-Lock for Ransomware Recovery, making ExaGrid the only backup storage system on the market to offer a non-network-facing tier with immutable objects and delayed deletes for ransomware recovery solution.
-
Recognition for its Tiered Backup Storage appliances, earning the following awards in the fall of 2020:
-
Network Computing Awards
- Company of the Year
- Hardware Product of the Year
-
Storage Awards “The Storries XVII”
- Enterprise Backup Hardware Vendor of the Year
- Storage Performance Optimisation Company of the Year
-
SDC Awards
- Storage Company of the Year
- Storage Hardware Innovation of the Year
- Vendor Channel Program of the Year
-
Network Computing Awards
ExaGrid’s Tiered Backup Storage offers a disk-cache Landing Zone for backup and restore performance and is tiered to a long-term retention repository for cost efficient storage with data deduplication as well as a scale-out storage architecture that scales as data grows. ExaGrid offers the best of both worlds by pairing the fastest backup and restore performance with the lowest cost long-term retention storage.
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid’s Retention Time-Lock is the only backup storage solution with a non-network facing tier, immutable objects and delayed deletes for ransomware recovery. Visit us at exagrid.com
or connect with us on LinkedIn
. See what our customers have to say about their own ExaGrid experiences, and learn why they now spend significantly less time on backup, in our customer success stories
.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005068/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
